Novo Nordisk is working with a digital health start-up to link better medication adherence to lower medicine costs for diabetes patients in the US through a text messaging pilot.
Sarepta Therapeutics has decided not to continue the development of vesleteplirsen, a follow-up to its Duchenne muscular dystrophy (DMD) therapy Exondys 51.
Investigator sites are essential for successful execution of clinical trials – ensuring studies are conducted ethically, safely, and in compliance with regulatory standards.
